Taligen Therapeutics Acquired for $111 Million

Cambridge biotech Taligen Therapeutics Inc. has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment.
Mass High Tech